MEDICLAIX: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
MEDICLAIX
Largest movements
- Cash +€75,459
up €75,459 (+168%), from €44,991 to €120,450
mainly Net result for the year (+€133,592) and Other debts (+€88,868)
- Receivables within one year +€10,843
up €10,843 (+9.5%), from €114,491 to €125,333
- Other debts +€88,868
up €88,868 (+82.0%), from €108,328 to €197,196
- Tax, wage and social debts -€3,402
down €3,402 (-8.9%), from €38,255 to €34,853
of which Remuneration and social security: -€3,965
- Gross operating margin +€12,595
up €12,595 (+7.7%), from €164,583 to €177,178
- Taxes +€2,956
up €2,956 (+8.1%), from €36,718 to €39,674
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €161,429 | €247,487 | +€86,058 | +53.3% |
| Fixed assets | 21/28 | €1,503 | €390 | -€1,113 | -74.1% |
| Tangible fixed assets | 22/27 | €1,503 | €390 | -€1,113 | -74.1% |
| Furniture and vehicles | 24 | €1,503 | €390 | -€1,113 | -74.1% |
| Current assets | 29/58 | €159,927 | €247,098 | +€87,171 | +54.5% |
| Amounts receivable within one year | 40/41 | €114,491 | €125,333 | +€10,843 | +9.5% |
| Trade receivables | 40 | €114,491 | €125,333 | +€10,843 | +9.5% |
| Cash at bank and in hand | 54/58 | €44,991 | €120,450 | +€75,459 | +168% |
| Deferred charges and accrued income | 490/1 | €445 | €1,314 | +€870 | +196% |
| Total equity and liabilities | 10/49 | €161,429 | €247,487 | +€86,058 | +53.3% |
| Equity | 10/15 | €13,281 | €13,874 | +€592 | +4.5% |
| Contributions | 10/11 | €500 | €500 | = | 0.0% |
| Profit (loss) carried forward | 14 | €12,781 | €13,374 | +€592 | +4.6% |
| Amounts payable | 17/49 | €148,148 | €233,614 | +€85,466 | +57.7% |
| Amounts payable within one year | 42/48 | €148,148 | €233,614 | +€85,466 | +57.7% |
| Financial debts | 43 | €692 | €0 | -€692 | -100% |
| Credit institutions | 430/8 | €692 | €0 | -€692 | -100% |
| Trade debts | 44 | €874 | €1,565 | +€691 | +79.1% |
| Suppliers | 440/4 | €874 | €1,565 | +€691 | +79.1% |
| Taxes, remuneration and social security | 45 | €38,255 | €34,853 | -€3,402 | -8.9% |
| Taxes | 450/3 | €34,290 | €34,853 | +€563 | +1.6% |
| Remuneration and social security | 454/9 | €3,965 | €0 | -€3,965 | -100% |
| Other amounts payable | 47/48 | €108,328 | €197,196 | +€88,868 | +82.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,379 | €1,113 | -€1,266 | -53.2% |
| Other operating charges | 640/8 | €387 | €400 | +€12 | +3.2% |
| Gross operating margin | 9900 | €164,583 | €177,178 | +€12,595 | +7.7% |
| Operating profit (loss) | 9901 | €161,817 | €175,665 | +€13,849 | +8.6% |
| Financial income | 75/76B | €36 | €0 | -€36 | -100% |
| Recurring financial income | 75 | €36 | €0 | -€36 | -100% |
| Financial charges | 65/66B | €2,353 | €2,399 | +€46 | +1.9% |
| Recurring financial charges | 65 | €2,353 | €2,399 | +€46 | +1.9% |
| Profit (loss) for the period before taxes | 9903 | €159,500 | €173,266 | +€13,767 | +8.6% |
| Income taxes | 67/77 | €36,718 | €39,674 | +€2,956 | +8.1% |
| Profit (loss) for the period | 9904 | €122,781 | €133,592 | +€10,811 | +8.8% |
| Profit (loss) for the period to be appropriated | 9905 | €122,781 | €133,592 | +€10,811 | +8.8% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 14 October 2026 via checked.be.